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Abstract This study aims to evaluate the effects of treatment
with IFN-β 1α on the expressions of NLRP3, NLRP1,
NLRC4, and AIM2, as inflammasomes, and caspase-1,
IL-1β, and IL-18, as the downstream molecules of
inflammasomes, in a population of Iranian multiple sclerosis
(MS) patients. In this study, 30 MS patients (22 women and 8
men) participated. Before receiving any medication and
6Â months after treatment with standard doses of IFN-β 1α
30Â mcg injected intramuscularly once a week, blood samples
were taken and then the leukocytes isolated, total RNAs ex-
tracted, and complementaryDNAs (cDNAs) synthesized. Gene
expressions of NLRP3, NLRP1, NLRC4, AIM2, and ASC
were evaluated at messenger RNA (mRNA) levels using real-
time PCR method; for assessing caspase-1 at protein level, the
Western blot method was used. The amounts of IL-1β and
IL-18 were measured in plasma using enzyme-linked immuno-
sorbent assay method. Analysis of the results before and after
therapy with IFN-β 1α in all patients shows significantly
decreased expressions of NLRP3, NLRC4, and AIM2. The
plasma levels of IL-1β, after treatment with IFN-β 1α, were
significantly decreased in theMS patients. Based on our results,
it appears that NLRP3, NLRC4, and AIM2 play critical roles
in the progression ofMS, probably by mediating Th1 and Th17
responses. It seems that decreased expression of IL-1β is
related to decreased production and also functions of
inflammasomes.
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Introduction
Multiple sclerosis (MS) is an inflammatory disease of the
central nervous system, characterized by demyelination in
the brain and spinal cord. Multiple sclerosis is also a chronic
disease that develops more likely in the age range of 20–
40 years, and its prevalence is higher in women than in men
[1]. In the type of relapse-remitting MS (RRMS), women are
involved twice compared to men [2]. The spread of MS has
been reported in different regions of the world, as in Europe
and America from 5 to 6 per 100,000 people suffer from MS
[3]. The prevalence of MS in Kerman city in the southeast of
Iran is 57.3/100,000 population [4]. In recent years, studies in
the Middle East and Iran suggest a relatively high prevalence
of the disease in these areas. Although the exact causes of the
disease are still unknown, some factors such as inheritance,
environmental factors, and even viral infections can be intro-
duced as the underlying causes of the disease [1, 5–7].
The formation of lesions or plaques, areas of inflammation,
demyelination, and gliosis in the central nervous system
(CNS) white matter are the main reasons for MS symptoms,
which can be diagnosed by magnetic resonance imaging
(MRI) technique [2]. Plaques in MS contain a variety of cells
* Gholamreza Asadikaram
gh_asadi@kmu.ac.ir
1 Neurology Research Center, Kerman University of Medical
Sciences, Kerman, Iran
2 Department of Laboratory Sciences, Faculty of Paramedicine,
Rafsanjan University of Medical Sciences, Rafsanjan, Iran
3 Neuroscience Research Center, Institute of Neuropharmacology,
Kerman University of Medical Sciences, Kerman, Iran
4 Endocrinology and Metabolism Research Center, Institute of Basic
and Clinical Physiology Sciences, Kerman University of Medical
Sciences, Kerman, Iran
5 Department of Biochemistry, School of Medicine, Kerman
University of Medical Sciences, Kerman, Iran
Mol Neurobiol
DOI 10.1007/s12035-016-9864-8
and inflammatory factors. Creation of wounds is due to de-
fects in the regulation of the immune system that leads to
increased proliferation, oligodendrocyte myelin, and subse-
quent T cell activity [8]. When T cells cross the blood–brain
barrier and enter the central nervous system, they cause un-
wanted reactions with the myelin-inflammatory loop that
leads to the creation of toxic substances and glial inflamma-
tion and results in axonal damage [2]. MS is a chronic disease
and disease progression varies from person to person.
Significantly more than 85 % of MS patients suffer primarily
from RR type [9]. RRMS has repeated periods of flares and
part of it is determined as full recovery. Of these patients,
about 50–60 %, between 10 and 15 years later, evolve to
secondary progressive MS and often have no periods of re-
lapse, but their symptoms are getting worse [10].
A small percentage of patients with MS (15 %) have more
severe degrees of nervous system defects, known as primary
progressive MS, who have recurrent episodes of mild defects
and are resistant to treatment [2]. Interferon-beta (IFN-β) is an
innate immune cytokine from interferon type 1 that acts on
multiple metabolic pathways [11]. Studies have shown that
MS patients are deficient in the production of IFN-β [12,
13]. Thus, exogenous interferon can cover the defect. These
cytokine types also play a crucial role in defending against the
virus by interfering with the IgG generation by the plasma, IgG
reduction, and adjusted cell function involved in the develop-
ment of MS, such as natural killer cells [14, 15]. The anti-
inflammatory features of interferon make it a significant com-
pound for the treatment of MS. Millward et al. showed that
treatment with IFN-β 1a with increasing interleukin (IL)-18
binding protein prevents IL-18 functions, preventing inflam-
mation [16]. Studies also showed that administration of IFN-β
levels of IL-18 also reduces MS [17]. The study by Inoue et al.
showed that IFN-β can improve inflammation in patients with
MS when they are related to the nucleotide-binding oligomer-
ization domain, leucine-rich repeat, and pyrin domain-
containing (NLRP)3 pathway [18]. In addition, studies have
shown that MS patients suffer from increased expression of
inflammatory molecules [19]. Inflammasomes may be the
most important molecule involved in inflammation.
Inflammasomes are a specific class of intracellular receptors
which recognize damage-associated molecular patterns
(DAMPs) or pathogen-associated molecular patterns
(PAMPs) to activate the caspase-1 enzyme [20]. The activated
form of caspase-1 provides, in turn, activation of the pre-
cytokines IL-1β and IL-18 [20]. Some NOD-like receptors
(NLRs), including NLRP1, NLRP3, and NLRPC4, and the
absent in melanoma 2 (AIM2) molecules are among the most
important families of inflammasomes [20]. It has been docu-
mented that IL-1β and IL-18 are the main cytokines involved
in the inflammation of MS [21]. Thus, it appears that expres-
sion of inflammasomes may be changed during MS. A study
on an animal model of MS (experimental allergic
encephalomyelitis, EAE) showed that inflammasomes are the
most important factors for the activation of caspase-1 and,
subsequently, activation of IL-1B and IL-18 to induce MS
[22]. Studies also showed that induction ofMS inmice without
apoptotic speck protein (ASC), the adaptor between
inflammasomes and caspase-1, is not possible [23]. However,
studies have shown that consuming drugs which mitigate the
effects of IL-18 can greatly help MS patients to be treated [24].
Given the role of inflammasomes in the induction of inflam-
mation and the role of IFN-β 1a in reducing inflammation, it
has been hypothesized that IFN-β 1a may affect inflammation
by altering the expression of inflammasomes. Therefore, this
study aims to evaluate the effects of treatment with IFN-β 1a
on the expressions of NLRP3, NLRP1, NLRC4, and AIM2, as
inflammasomes, and apoptosis-associated speck-like protein
containing a carboxy-terminal CARD (ASC), caspase-1,
IL-1β, and IL-18, as the downstream molecules of
inflammasomes, in a population of Iranian MS patients.
Material and Methods
In this study, 30 MS patients (22 women and 8 men) were
examined before receiving any medication. Diagnosis of MS
according to the revised McDonald criteria and based on ra-
diology, laboratory, clinical, and neurologist observations was
conducted [25]. All patients signed an informed consent form
to enter the project. Participants in the study did not suffer
from any other inflammatory diseases such as allergy, autoim-
mune diseases, diabetes types 1 and 2, and heart and kidney
diseases. Patients with infectious diseases and under treatment
of immunomodulatory medications were excluded from the
study. Research permits were obtained from Kerman
University of Medical Sciences Ethics Committee, with li-
cense number k/92/587. Prior to receiving drug IFN-β 1a
(IFN-β pharmaceutical company’s CinnaGen composition as
the commercial name of Cinnovex, similar to the composition
of Avonex), 10 mL of venous blood was collected in tubes
containing ethylenediaminetetraacetic acid (EDTA) anticoag-
ulant and centrifuged for 5 min at 2500 rpm; about 0.5 mL of
plasma was separated and then the leukocytes were isolated
using Ficoll. Total RNAs were purified and complementary
DNAs (cDNAs) were synthesized immediately after leuko-
cyte isolation. The synthesized cDNAs and plasma were
stored at –70 °C for further analysis. Six months after treat-
ment with standard doses of IFN-β 1a, blood samples were
taken on the basis of previous studies [19]. Just like before,
samples were taken for the analysis of plasma, leukocyte iso-
lation, total RNA extraction, and cDNA synthesis and were
saved thereafter. Gene expressions of NLRP3, NLRP1,
NLRC4, AIM2, and ASC were evaluated at messenger
RNA (mRNA) levels using real-time PCR method; for
assessing caspase-1 at protein level, the Western blot method
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was used. The amounts of IL-1β and IL-18 were measured
using enzyme-linked immunosorbent assay (ELISA) method,
as described below.
RNA Purification, cDNA Synthesis, and Real-Time PCR
Condition
To extract total RNA from patient specimens, a Trizol solution
(Bioneer, South Korea) was used. The unity and integrity of
RNA was confirmed by agarose gel electrophoresis (1.5 %),
and the amount of RNA and the purity and quality of RNA
were tested by a photometric and spectrophotometric method
at OD260/OD280 nm. Then, using oligo-dT primer and
cDNA synthesis kit from the Takara kit (Takara Co., Japan),
cDNAwas prepared from purified RNA according to the man-
ufacturer’s instructions.
The expressions of NLRP3, NLRP1, NLRC4, AIM2, and
ASC were evaluated using appropriate primers (Table 1) and
the master mix containing dye SYBR Green (Takara Co.) in a
real-time PCR machine (Corbet, Australia) using the follow-
ing program: 3 min at 95 °C, followed by 43 cycles of dena-
turation (10 s), annealing (10 s), and extension. It should be
noted that β.Actin was used as the housekeeping gene.
At the end of the process, the expressions of these mole-
cules before and after treatment were computed using the
2–ΔΔCT formula.
Western Blotting
In this study, the caspase-1 molecule was measured by
Western blotting and the data analyzed using ImageJ software.
Briefly, protein extraction was performed using the Ripa buff-
er method and the protein concentration was measured by the
bicinchoninic assay (BCA) method. Then, the lysate was
equally separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE).
The gel was then transferred to polyvinylidene difluoride.
For Western blotting, a primary antibody, anti-caspase-1
(1:400; Santacruz Biotechnology, Santa Cruz, CA), was incu-
bated for 1 h and then rinsed with Tris-buffered saline and
Tween 20 (TBST) buffer, incubated with secondary antibody
with horseradish peroxidase (1:20,000; Abcam), and finally
was incubated for 1 h.
Henceforth, rinsing was performed with TBST three times
and then using fluorescence light, produced by enhanced
chemiluminescence (BioRAD), and finally determined with
the help of a photographic film. The protein β-actin was used
as the housekeeping protein.
ELISA Method
To measure the plasma levels of IL-18 (Eastbiopharm,
Torrance, CA) and IL-1β (R&D, Minneapolis, MN), the
ELISA method was used according to the manufacturer’s
protocols.
Data Analysis
Data analysis was performed using SPSS-20 software. To
determine the effect of gender and time on the expressions
of the evaluated molecules, two-way repeated-measures
ANOVA was used. However, due to the interaction be-
tween sex and time, paired Student’s t test was used for
comparison of the data before and after treatment with
IFN-β 1a in all patients and for each sex separately, too.
All results are reported as mean ± SEM. p ≤ 0.05 as the
significance level was reported.
Results
Among the 30 patients enrolled, 22 were women (73 %). The
results revealed that all of the patients were responders to the
IFN-β 1a therapy and have not shown recurrence in MS dur-
ing treatment with IFN-β 1a.
Analysis of the results before and after therapy with IFN-β
1a in all patients showed decrement in the expressions of the
genes of interest (NLRP3, p = 0.047; NLRP1, p = 0.246;
NLRC4, p=0.049; AIM2, p=0.052; and ASC, p=0.116).
But only in three cases (NLRP3, NLRC4, and AIM2) was
the reduction significant (Fig. 1).
The patients were divided into two groups, male (n=8) and
female (n=22). After treatment with IFN-β 1a, the expres-
sions of all measured genes were decreased in women
(NLRP3, p=0.050; NLRP1, p=0.127; NLRC4, p=0.055;
AIM2, p=0.092; and ASC, p=0.121). But just about the
NLRP3 difference was significant. No significant differences
were observed before and after treatment with IFN-β 1a in















men: NLRP3, p=0.643; NLRP1, p=0.58; NLRC4, p=0.684;
AIM2, p=0.573; and ASC, p=0.789 (Fig. 2).
Protein Results
The data analysis of caspase-1 showed that, 6 months after
treatment with IFN-β 1a, the amount of caspase-1 was de-
creased, but this decline was not significant in all patients
(p=0.439), females (p=0.55) and males (p=0.64; Fig. 3).
The plasma levels of IL-1β (p= 0.035), but not IL-18
(p=0.387), after treatment with IFN-β 1a were significantly
decreased in MS patients, while IL-1β did not differ among
female (p=0.065) and male (p=0.138) patients (Figs. 4 and
5). IL-18 levels also were not changed in female (p=0.43) and
male (p=0.22) patients (Figs. 4 and 5).
Discussion
Inflammasomes are the main molecules involved in the induc-
tion of inflammation via promotion of pro-IL-1β and pro-IL-
18 cleavage [26]. There are several investigations which have
confirmed the pathologic roles played by inflammasomes and
their related downstream molecules, including ASC, caspase-
1, IL-1β, and IL-18, in the pathogenesis of MS [27, 28].
Inflammasome activations are associated with neuroinflamma-
tion complications such as mitochondrial dysfunction, release
of circulating DNA, secretion of reactive oxygen species, and
potassium effluxes [29]. Therefore, it can be hypothesized that
the molecules and their downstream molecules can be consid-
ered as risk factors for MS. Our results showed that IFN-β 1a,
as an interferon therapy, can improve the clinical presentation
by blocking relapse in treated patients. Therefore, it seems that
Fig. 1 Bar graph showing the
measured changes in gene
expression before and after
treatment with IFN-β 1a. All the
genes were downregulated
6 months after therapy with IFN-
β 1a, but only NLRP3
(p = 0.047), NLRC4 (p= 0.049),
and AIM2 (p = 0.052) show
significant reduction in
expression levels. The number of
participants was 30 and the data
reported as mean± SEM. p ≤ 0.05
was considered significant
Fig. 2 Bar graph showing the measured changes in gene expression
before and after treatment with IFN-β 1a in males (n= 8) and females
(n = 22). All the genes were downregulated after drug treatment, but only
in females was the expression level of NLPR3 decreased significantly
(p = 0.05). The data were reported as mean ± SEM. p ≤ 0.05 was
considered significant
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the Iranian version of IFN-β 1a is suitable for the treatment of
Iranian RRMM. The results also revealed that IFN-β 1a mod-
ulates the expression of some inflammasomes, including
NLRP3, NLRC4, and AIM2 (but not NLRP1), at mRNA
levels. The results also demonstrated that the plasma levels of
IL-1β were significantly decreased in IFN-β 1a-treated pa-
tients. In accordance with the fact that IL-1β is secreted from
immune and non-immune cells after cleavage (activation),
hence, it may be concluded that decreased expression of IL-
1β is related to the decreased production and also functions of
inflammasomes. Based on our results, it may be hypothesized
that IFN-β 1a improves the clinical presentation of MS via
decreasing the plasma levels of IL-1β in a NLRP3-,
NLRC4-, and AIM2-dependent manner. Previous studies re-
vealed that NLRC4, NLRP3, and AIM2 recognize PAMPs and
DAMPs, while NLRP1 almost recognizes narrow ranges of
PAMPs [30]. Thus, it is plausible that IFN-β 1a targets
inflammasomes which are activated by various ranges of
PAMPs and DAMPs, the ligands released in autoimmune dis-
eases, including MS. Accordingly, NLRP3 can be activated
not only by microbial PAMPs but also by various ranges of
endogenous DAMPs, including uric acid crystals, alum, reac-
tive oxygen species, intercellular ATP, silica, and amyloidal-β
[31–33]. AIM2 is also able to recognize self-DNA from apo-
ptotic cells and activate caspase-1 via ASC [34]. Collectively,
due to the results presented here, it appears that IFN-β 1a
targets the pathways which lead to the downregulation of the
most important inflammasomes involved in MS. A study by
Malhotra and colleagues revealed that, although the mRNA
levels of NLRP3 and IL-1β after 24 months of treatment with
IFN-β were increased in responder MS patients, their expres-
sions were lower in comparison to non-responder MS patients
[35]. Interestingly, their results also demonstrated that IFN-β
therapy has no effect on the expressions of NLRP1 and IL-18
[35]. Additionally, their results showed that IFN-β therapy has
not altered the expression of NLRC4 [35]. Based on our results
which revealed that the expressions of NLRP3 and IL-1βwere
decreased after therapy with IFN-β 1a, the results of Malhotra
were in contrast with ours. Due to the fact that our results
revealed sex-dependent effects of IFN-β 1a on the expression
Fig. 3 Caspase-1 was measured
by Western blotting in patients
before and after treatment with
IFN-β 1a. The number of patients
was 30 and data in three groups—
all patients, female group (22
patients), and male group (8
patients)—were observed.
Caspase-1 expression was
decreased after treatment in MS
patients (p=0.439), female group
(p=0.55), and male group
(p=0.64), but the differences were
not significant. Data were reported
as mean ±SEM. p≤ 0.05 was
considered significant. β-Actin
was used as the control protein
Fig. 4 IL-18 was tested by
ELISA in plasma before and after
treatment with IFN-β 1a. IL-18
level reduced after treatment in
MS patients, but not significantly
(p = 0.387). The plasma levels of
IL-18 were not changed after
treatment in males (p= 0.22) and
females (p= 0.43). Data are
reported as mean± SEM. p< 0.05
was considered significant
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of NLRP3, hence, it may be proposed that the differences
between participants regarding sex or other ethnic variations
may be the reasons for the discrepancy. However, their results
approved the effects of IFN-β 1a therapy on the expressions of
NLRP3 and IL-1β in responders, which were lower than in
non-responders. Another study on an animal model of MS
(EAE) showed that IFN-β 1a suppresses NLRP3 activation
and ameliorates EAE [36]. Inoue and colleagues reported that
IFN-β 1a therapy in an animal EAE model is effective only
when the development of EAE depends on NLRP3 [37]. In
parallel with our results, Guarda et al. demonstrated that IFN-β
1a inhibits IL-1β production and activation [38]. Collectively,
based on our results and the mentioned studies, it appears that
NLRP3, NLRC4, and AIM2, as inflammasomes, play critical
roles in the progression ofMS, probably by mediating Th1 and
Th17 responses [26].
Our results also showed that the mRNA levels of ASC and
the protein levels of caspase-1 were not altered following treat-
ment with IFN-β 1a. Based on the fact that ASC and caspase-1
play as the adaptor and enzyme proteins, respectively, and that
they exist in the cytoplasm and ready to be activated by inflam-
mations, so, it seems that IFN-β 1a decreases their functions,
rather than expressions, by decreasing the expressions of
NLRP3, NLRC4, and AIM2. The results were also confirmed
by previous investigations [35]. Additionally, due to the re-
sults, NLRP1 did not change after treatment with IFN-β 1a;
therefore, it may be hypothesized that ASC and caspase-1 may
be used by NLRP1, hence their unchanged expressions after
IFN-β 1a therapy. It seems that more studies on the effects of
IFN-β therapy on NLRP1 and also its related molecules (ASC
and caspase-1) can shed light to improve our knowledge.
The results also demonstrated that the expression of
NLRP3 has been decreased in female patients, but not in
males, following 6 months of IFN-β 1a therapy. Due to the
fact that the expression of NLRP3 in all participants was sig-
nificantly decreased following IFN-β 1a therapy, it seems that
the decline is sex dependent and that women were more sen-
sitive than men to IFN-β 1a. In contrast, although the serum
levels of IL-1β and the mRNA levels of NLRC4 and AIM2
were significantly decreased after 6 months treatment with
IFN-β 1a, their values in females and males were not signif-
icant. So, it appears that the decreased expressions of the mol-
ecules following IFN-β 1a therapy were sex independent.
Accordingly, the authors suggested that more studies need to
be performed to explore the roles of gender on the expression
of NLRP3 in MS.
Conclusion
Based on our results, it seems that IFN-β 1a decreases inflam-
mation via NLRP3, NLRC4, and AIM2 expressions, which
can lead to decreased cleavage of IL-1β and IL-18, which play
key roles in the pathogenesis of multiple sclerosis. The main
pathway used by IFN-β 1a for decreasing the expressions of
NLRP3, NLRC4, and AIM2 has yet to be clarified, but it may
be hypothesized that it downregulates the inflammasomes di-
rectly, via affecting the responsible transcription factors, and
indirectly, via affecting the positive related pathways.
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